Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: EyeDrMike who wrote (5423)	2/11/1998 12:54:00 PM
From: mc	Respond to of 23519

Well done, Mike. Thanks for clearing that up for us. Good luck, Gary

To: EyeDrMike who wrote (5423)	2/11/1998 4:52:00 PM
From: Evan Dimmer	Read Replies (1) \| Respond to of 23519

For the second time now.......any thoughts? INTERVIEW-Astra sees scope for acquisitions STOCKHOLM, Feb 11 (Reuters) - Swedish drugs group Astra (ASTRa.ST) said on Wednesday its lower sales growth rate of 15 percent opened up opportunities for making acquisitions. ''When we were growing at 30 percent it would have been wrong to carry out large acquisitions. But today, growth is about half of that, and so you can spice things up a bit with strategic changes or corporate acquisitions,'' Astra CEO Hakan Mogren told Reuters in an interview. Mogren said he would not rule out the company initiating a large purchase during the year. "We can not rule out anything," he said. A strong balance sheet meant the company had a certain degree of freedom regarding financing future investments, Mogren said. ''There is an enormous spectrum. Today we have an internal financing ratio of 74 percent and we can consider going down to 30 percent for example,'' Mogren said. ''Finances would not be the limiting factor, but what is considered achieveable.'' He stopped short of giving more details about what projects the company was evaluating. ''You must respect the fact that it would be tragic if a plan was wrecked because it was leaked to the market or to the affected parties,'' Morgen said. About merger fever in the drug sector globally, Mogren said ''it would be tragic if the view was that everyone had to merge for the sake of merging. ''At the same time, it would be correct for certain companies to merge, as it would be incorrect for other companies not to merge. Each deal must be considered individually.'' Asked if a project included U.S. licensing partner Merck (MRK - news), Mogren said: ''I can not comment on that.'' Mogren also said the pace of increase of marketing costs in the U.S. would decline. He also said Astra-Merck and its own wholly owned U.S. subsidiary Astra Inc had built up a large sales force. "We have now built up the marketing organisation which we